These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16454155)

  • 1. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ; Sternon J
    Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of zoledronic acid for Paget's disease of bone.
    Maricic M
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 13. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
    Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP; Manicourt DH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
    J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Paget's disease of bone: a survey of clinical practice in Australia.
    Walsh JP; Attewell R; Stuckey BG; Hooper MJ; Wark JD; Fletcher S; Ferrari V; Eisman JA
    Bone; 2008 Jun; 42(6):1219-25. PubMed ID: 18353737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR; Maslowski K
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of a single dose of zoledronic acid in a case of Paget bone disease].
    Saban M; Fidalgo S; Díaz CA; Lutfi RJ
    Medicina (B Aires); 2010; 70(5):445-8. PubMed ID: 20920964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.